CureVac's Potential Has Wall Street Sending Mixed Signals

Motley Fool

26 Apr 2021 0 shares 1 views

Motley Fool

Published 26 Apr 2021

The biotech still has a long way to go to prove itself and justify its current stock valuation.

Dow, S&P 500 end flat while tech slump burdened Nasdaq

12:10pm: Tesla shares slow despite record net income In the US, the Dow has recovered from its early weakness, landing at just 15..

Proactive Investors 27 Apr 2021

12:10pm: Tesla shares slow despite record net income In the US, the Dow has recovered from its early weakness, landing at just 15..

Proactive Investors 27 Apr 2021